Overview

ChemTree helps assay developers who perform low throughput screening to enhance their drug discovery throughput, generating higher quality leads with less time and fewer resources.

Problem:

Many compounds are poor candidates due to non-specific binding.

Solution:

Use the same initial random screening set for each new screening program, and use the ChemTree multivariate recursive partitioning sequential screening paradigm to drive selection of compounds that bind specifically to the target of interest and not to other targets. An IP asset is built up over time, allowing better and better predictions of target selectivity.